Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Huntington's Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

NCT00788047
View directory record Official record
Conditions
Huntington Disease, Alzheimer Disease
Interventions
Dextromethorphan, Dimebon + Dextromethorphan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2009 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

NCT00990613
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon IR, Dimebon Transdermal
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Not applicable Interventional

Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

NCT03417583
View directory record Official record
Conditions
Huntington Disease
Interventions
Protocol Intervention Group
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Sep 30, 2026, 10:31 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 30, 2026, 10:31 PM EDT
Completed No phase listed Observational

FuRST 2.0 Cognitive Pre-Testing

NCT02881931
View directory record Official record
Conditions
Huntington's Disease
Interventions
FuRST 2.0
Behavioral
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Englewood, Colorado • Wichita, Kansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821
View directory record Official record
Conditions
Huntington Disease
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Los Alamitos, California • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 30, 2026, 10:31 PM EDT
Completed No phase listed Observational

Development of the Virtual Unified Huntington's Disease Rating Scale

NCT05748288
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Huntington Study Group
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 30, 2026, 10:31 PM EDT
Active, not recruiting Phase 2 Interventional

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551
View directory record Official record
Conditions
Huntington Disease
Interventions
Tominersen, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 50 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 10:31 PM EDT
Not listed Not applicable Interventional

PHysical Activity and Exercise Outcomes in Huntington's Disease

NCT03344601
View directory record Official record
Conditions
Huntington Disease
Interventions
physical activity
Behavioral
Lead sponsor
Cardiff University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Sep 30, 2026, 10:31 PM EDT
Completed No phase listed Observational

FuRST 2.0 Cognitive Pre-testing - Round 2

NCT03709173
View directory record Official record
Conditions
Huntington Disease
Interventions
FuRST 2.0
Behavioral
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Englewood, Colorado • Wichita, Kansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 30, 2026, 10:31 PM EDT
Not listed Phase 4 Interventional

A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

NCT02509793
View directory record Official record
Conditions
Huntington's Disease
Interventions
Tetrabenazine
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

NCT00970229
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease
Interventions
[123I]MNI-420
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 2 Interventional

Creatine Safety and Tolerability in Premanifest HD: PRECREST

NCT00592995
View directory record Official record
Conditions
Huntington Disease
Interventions
Creatine monohydrate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
26 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

NCT03842969
View directory record Official record
Conditions
Huntington Disease
Interventions
RO7234292 (RG6042)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 1Phase 2 Interventional

Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD

NCT03306888
View directory record Official record
Conditions
Huntington's Disease
Interventions
Physical Activity Coaching
Other
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 30, 2026, 10:31 PM EDT
Completed No phase listed Observational

Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD

NCT00491842
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 2 Interventional Results available

Creatine Safety & Tolerability in Huntington's Disease

NCT01412151
View directory record Official record
Conditions
Huntington's Disease (HD)
Interventions
Creatine monohydrate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Sep 30, 2026, 10:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Risk: Whether, When, and How to Tell Adolescents

NCT03421327
View directory record Official record
Conditions
Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 1Phase 2 Interventional

Creatine Therapy for Huntington's Disease

NCT00026988
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
Boston, Massachusetts • Long Island City, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Sep 30, 2026, 10:31 PM EDT
Completed No phase listed Observational

Making HD Voices Heard

NCT05268029
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Huntington Study Group
Network
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

NCT00831506
View directory record Official record
Conditions
Alzheimer Disease, Huntington Disease
Interventions
digoxin, dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Sep 30, 2026, 10:31 PM EDT
Not listed Phase 1 Interventional

Ursodiol in Huntington's Disease

NCT00514774
View directory record Official record
Conditions
Huntington Disease
Interventions
ursodiol, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NCT00824590
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Sep 30, 2026, 10:31 PM EDT
Completed Phase 2 Interventional

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

NCT02481674
View directory record Official record
Conditions
Huntington's Disease
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
21 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 30, 2026, 10:31 PM EDT